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Investigating the epidemiology of medication errors in 
adults in community care settings
A retrospective cohort study in central Saudi Arabia
Ghadah A. Assiri, B Pharm, MSc, Abdullah HM Alkhenizan, MD, CCFP, Salma M. Al-Khani, B.Pharm, MHHA,
Liz M. Grant, PhD, MA, Aziz Sheikh, MD, MBBS.
ABSTRACT
 راطتخلإا لماوعو ينمزلا  راشتنلاا لدعم نم ققحتلا  :فادهلأا
 ءاودلا ةرادإ يف ةبقارلماو فصولا ةيحان نم ًايريرس ةمهلما ءاطخلأل
 .ةيعمتجلما ةياعرلا يف مهتنياعم متت نيذلا ينغلابلا ىضرلما ىدل
 تانايب  يعجر  رثأب  ةيبارتلأا  ةساردلا  هذه  تمدختسا  :ةقيرطلا
 ةيئاوشع ةنيع رايتخا تم .)HER( ةينورتكللإا ةيحصلا تلاجسلا
 ةرسلأا بط تادايع ةرايز يف )اماع 18( غلاب صخش 2000 مضت
 ،ضايرلا ،ثاحبلأا زكرمو يصصختلا لصيف كللما ىفشتسم يف
 رهشأ 3 تانايبلا عمج ةيلمع تقرغتسا .ةيدوعسلا ةيبرعلا ةكلملما
 ىدم نم ققحتلاب انمق .)م2017 ربمسيد ىلإ ربوتكأ لوأ نم(
 ءاطخلأا  رطلخ  ينضرعلما  ىضرلماب  ةطبترلما  رطلخا  لماوعو  راشتنا
 فوحتلا  ةجذنمو  ةيفصولا  تلايلحتلا  تيرجأ  .ًايريرس  ةماهلا
.)14 رادصلإا( STATA ءاصحلإا جمانرب مادختساب يتسجوللا
 
 ينمزلا  راشتنلاا  لدعم  نأ  ةيبارتلأا  انتسارد  تفشك  :جئاتنلا
 ةقث  لصاف(  8.1%  وه  ًارهش  15  ىدم  ىلع  ةيئاودلا  ءاطخلأل
 ىضرلماب  ةطبترلما  راطتخلإا  لماوعو  )CI( 95% )6.5-9.7(
 سنلجا  ،ماع  ≥65  رمعلا  :يه  ةيئاودلا  ءاطخلأا  رطلخ  ينضرعلما
 رثكأ وأ سمخ مادختساو ،ضيرملل ةيدوعسلا ةيسنلجا ،يركذلا
 .ةنمازتلما ةيودلأا نم
 يف  ةيئاودلا  ءاطخلأا  يف  ثحبت  ةسارد  لوأ  يه  هذه  :ةتمالخا
 نأ  اندجو  .ةيدوعسلا  يف  ةيعمتجلما  ةحصلا  ةياعرلا  تاعاطق
.ةعئاش ةيودلأا ةبقارم وأ فصوب ةقلعتلما ءاطخلأا
Objectives: To investigate the period prevalence 
and risk factors for clinically important prescription 
and monitoring errors among adults managed in 
community care in Saudi Arabia (SA).
Methods: This retrospective cohort study 
used electronic health record (HER) data. A 
random sample comprising of 2,000 adults 
(≥18 years old) visiting Family Medicine clinics 
in King Faisal Specialist Hospital and Research 
Center (KFSH & RC), Riyadh, SA, was selected. 
Data collection took 3 months (October December 
2017).  Descriptive analyses and logistic regression 
modeling were performed using STATA (version 14) 
statistical software.
Results: The overall period prevalence of medication 
errors over 15 months was 8.1% (95% confidence 
interval [CI] 6.5-9.7). Risk factors that significantly 
predicted overall risk of patients experiencing one 
or more medication errors were: age ≥65 years, male 
gender, Saudi nationality, and polypharmacy (defined 
as the concurrent use of ≥5 drugs).
Conclusions: Clinically important medication errors 
were commonly observed in relation to both drug 
prescription and monitoring. 
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Patient safety is a public concern in healthcare systems across the world.1 Medication errors are a 
major problem across care settings, including home, 
ambulatory, and primary care (henceforth community) 
settings.1 The World Health Organization (WHO) has 
identified medication errors as key focus areas for the 
enhancement of patient safety in community settings.2 
A recent systematic review revealed considerable 
variations in the prevalence rates of medication errors 
in community settings. This result, at least in part, 
reflects variations in: i) the definitions of medication 
errors used in studies, ii) the populations studied, 
iii) the methodologies employed for error detection, 
and iv) the outcome measures studied.3 This systematic 
review also highlighted the absence of studies focusing 
on medication errors in community settings in the 
Kingdom of  Saudi Arabia (KSA). The pharmacist-led 
information technology intervention for medication 
errors (PINCER) trial is among the world’s first 
randomized studies that aimed to reduce the risk of 
medication errors in general practice. A validated 
tool for the measurement of medication errors was 
developed by Avery et al4 and was used in the PINCER 
trial in the United Kingdom (UK). This trial shows that 
the PINCER intervention is more effective than simple 
feedback for reduction of the numbers of patients at 
risk from prescribing and monitoring errors in general 
practice. 
The objectives of this study were to investigate the 
epidemiology of clinically important errors in medicine 
management, as defined by the PINCER trial4 and risk 
factors for clinically important errors among adults 
managed in community care in SA. 
Methods. The current study was divided into 3 
phases: a feasibility phase, pilot retrospective cohort 
phase, and retrospective cohort study.  The feasibility 
phase involved the identification of sites in SA with 
ambulatory electronic health record (EHR) data for 
the investigation of issues pertaining to the accessibility 
and completeness of data, and which provided the 
opportunity for the dataset to be used in outcome 
evaluation (Table 1). The PINCER trial focused 
on a pre-specified list of clinically important errors 
in prescription and monitoring stages of medicine 
management.4
The pilot phase involved testing: i) sample generation, 
ii) data extraction, and iii) outcome assessment on a 
randomly selected sample of 200 patients. This article 
focuses on the pilot phase and the main retrospective 
cohort study.
The research protocol, data collection sheet, and 
waiver of informed consent (in place of individual 
informed consent) were approved by the Clinical 
Research Committee and the Research Ethics 
Committee (REC) of the Office of Research Affairs, 
King Faisal Specialist Hospital and Research Center 
(KFSH & RC), Riyadh (project # 2171 060), KSA. 
Several ambulatory care centers in Riyadh were 
contacted for fieldwork selection. Family Medicine 
clinics in KFSH & RC, Riyadh, SA were selected. 
A random sample of patients visiting the Family 
Medicine clinics in KFSH & RC was generated, and 
the follow-up was performed retrospectively over the 15 
months before data extraction. Data collection took 3 
months (October 2017 to  December 2017). Electronic 
records were selected using a random number table 
that was generated using the “simple random sample 
without replacement” function in STATA (version 14).
The inclusion criteria were: i) Saudi and non-Saudi 
adults aged 18 years or older, ii) patients who had been 
registered with the Family Medicine clinics at KFSH & 
RC for at least 15 months prior to data extraction, and 
iii) patients recorded as receiving at least one prescribed 
or over-the-counter (OTC) medication. These 
medications were checked against the Saudi Food and 
Drug Authority (FDA) list of human medications and 
were subsequently classified into prescription or OTC 
medications.5 Patient records were excluded if they did 
not fulfill the inclusion criteria. 
The patients’ recorded baseline characteristics were 
as follows: i) age, ii) gender, iii) nationality (Saudi, 
non-Saudi), iv) diagnosis or underlying conditions, 
v) OTC medication use recorded at any point during 
the 15 months, and vi) polypharmacy (≥5 medications 
at any point during the 15 months). The exposures of 
interest were the risk factors, and prescription and/or 
OTC drug. 
The outcome variables were: i) period prevalence 
of the primary, secondary, composite secondary, and 
revised updated outcome measures, ii) patient and 
medication-related risk factors (age, gender, nationality, 
polypharmacy and OTC medicine use), and iii) 
physician-related risk factors: age (18-50 years, ≥51 
years), gender, nationality (Saudi, non-Saudi), number 
Disclosure. Authors have no conflict of interests, and 
the work was not supported or funded by any drug 
company.  The project was financially supported by the 
Prince Abdullah bin Khalid Celiac Disease Research 
Chair, Vice Deanship of Scientific Research, King Saud 
University, Riyadh, Kingdom of Saudi Arabia.  
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of physicians involved in a patient’s care (one, more 
than one), certification (American, British, Canadian, 
Jordanian, or none), and number of years of experience 
(1-9 years or ≥10 years). For details on the primary, 
secondary, composite secondary, and revised updated 
outcome measures are summarize in Table 1.4,6 
We then compared the results of the cohort study 
with the baseline results of the UK PINCER trial,4 
which were derived through QResearch database 
interrogation.7
Data sources/measurement. After the selection of 
a random sample from the Family Medicine clinics, 
in-depth EHR screening, involving the assessment of 
diagnostic, medication list, and laboratory data, was 
conducted. 
Development of a data collection tool and process. 
A paper-based data collection form was used to extract 
summary descriptions of all the relevant information 
available in the EHRs to gather each patient’s 
demographics and outcome measures (Appendix 1). 
The information obtained was transferred to an Excel 
spreadsheet for analysis. The electronic data sheet 
was stored in a password-protected computer and no 
patient-identifying information was recorded.
Manual data extraction from the EHRs, involving 
200 records, was independently undertaken for the pilot 
retrospective study. For the main cohort study, data 
extraction was performed for all 2,000 records, while 
a second trained reviewer undertook the independent 
assessment of a random 10% of the sample of records.8,9 
Any discrepancy or disagreement was discussed and 
resolved through double-checking of records or 
arbitration if a decision could not be reached.
To reduce the risk of selection bias in sampling, 
simple random sampling was employed. The 
independent evaluation of a sample of records was 
designed to minimize the risk of information bias.10 
For the cohort study, the largest sample size that 
was feasible given: i) the time available, ii) resources, 
iii) research team number, and iv) the manual method 
employed for data extraction resulted in a total of 
2,000 records. A sample size of 10% or more of the 
major study size is commonly deemed adequate for 
Table 1 - Outcome measures from the Pharmacist-led information technology intervention for medication errors (PINCER) trial and the revised 
updated PINCER.7,10
Outcome measures
Primary outcomes
1. Patients with a history of peptic ulcer who have been prescribed a non-selective, NSAID without co-prescription of a PPI
2. (2a) Patients with asthma who have been prescribed a beta-blocker
3. Patients aged 75 years and older who have been prescribed an ACE, or a loop diuretic long-term, who have not had a computer-recorded 
check of their renal function and electrolytes in the previous 15 months
Secondary outcomes
(2b) Patients with asthma  (and no history of CHD) who had been prescribed a beta-blocker
4. Proportion of women with a past medical history of venous or arterial thrombosis who had been prescribed the combined oral contraceptive 
pill
5. Patients receiving methotrexate for at least 3 months who had not had a full blood count recorded (5a), or liver function test (5b), in the 
previous 3 months
6. Patients receiving warfarin for at least 3 months who had not had a recorded check of their INR in the previous 12 weeks
7. Patients receiving lithium for at least 3 months who had not had a recorded check of their lithium concentrations in the previous 3 months
8. Patients receiving amiodarone for at least 6 months who had not had a thyroid function test in the previous 6 months
9. Patients receiving prescriptions of methotrexate without instructions that the drug should be taken every week
10. Patients receiving prescriptions of amiodarone for at least 1 month who are receiving a dose of more than 200 mg per day
Composite secondary outcome measures
11. Patients with at least one prescription problem (a combination of outcome measures #1,# 2, or# 4)
12. Patients with at least one monitoring problem (a combination of outcome measures #3, #5, #6, #7, and #8)
Additional revised updated outcome measures 
13. Prescription of an oral NSAID, without co-prescription of an ulcer-healing drug, to a patient aged ≥ 65 years
14. Prescription of an anti-platelet drug, without co-prescription of an ulcer-healing drug, to a patient with a history of peptic ulceration
15. Prescription of warfarin or NOAC in combination with an oral NSAID
16. Prescription of warfarin or NOAC and an anti-platelet drug in combination, without co-prescription of an ulcer-healing drug
17. Prescription of aspirin in combination with another anti-platelet drug, without co-prescription of an ulcer-healing drug
18. Prescription of a long-acting beta-2 agonist inhaler (excluding combination products with inhaled corticosteroid) to a patient with asthma 
who is not also prescribed an inhaled corticosteroid
19. Prescription of an oral NSAID to a patient with heart failure
20. Prescription of antipsychotics for >6 weeks in a patient aged ≥ 65 years with dementia but not psychosis
21. Prescription of an oral NSAID to a patient with eGFR <45
ACE - angiotensin converting, beta-blocker - beta-blocker, CHD - coronary heart disease, eGFR - estimated glomerular filtration rate, 
INR - international normalized ratio, NOAC - new oral anti-coagulant, NSAID -  non-steroidal anti-inflammatory drug, PPI - proton-pump inhibitor, 
Outcome number 2 has two parts: (2a) and (2b).
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pilot studies;11 thus, 200 patient records were randomly 
selected for the pilot phase.
Data access and data cleaning methods. Data access 
and cleaning methods were used as per the PINCER 
trial protocol.6,7 The electronic data sheet was checked 
for errors in data entry, outliers, and missing data. An 
inventory of medical record numbers and each patient’s 
code number was used to ensure that the same patient 
was not included in the dataset more than once.
Statistical analysis. Microsoft Excel was used to 
manage and process data; STATA (version 14) was used 
to analyze the data. 
The overall period prevalence rate of patients with 
at least one error was calculated as: “the number of 
patients experiencing one or more medication error 
at any time during the 15-month period (numerator)/
the total number of patients in the study population 
(denominator)”.12  
The overall period prevalence rate of medication 
errors was calculated as follows: “the number of 
medication errors at any time during the 15-month 
period (numerator)/the total number of patients in the 
study population (denominator)”. 
The prevalence of each outcome measure was 
described using: i) numerators, ii) denominators, and iii) 
percentages at patient level, as detailed in the PINCER 
trial protocol.6,7 To illustrate patients’ demographic 
characteristics and diagnoses, descriptive statistics in 
terms of frequency counts and proportions were used. 
To evaluate the association between the risk factors and 
outcomes, we performed logistic regression modeling. 
The results of the regression analysis were presented in 
terms of odds ratios (OR) with their 95% confidence 
intervals (CIs). For logistic regression modeling, the 
dependent variable was defined as the presence/absence 
of the outcome or, more fully, the presence/absence 
of patients at risk of clinically important errors.  To 
determine the agreement between the 2 independent 
data extractors, a Kappa coefficient was calculated. A 
Kappa score: is a measure of inter-rater agreement for 
categorical variables.13 Landis and Koch suggested that 
a Kappa value lower than 0.40 denotes poor-to-fair 
agreement, 0.41-0.60 moderate agreement, 0.61-0.80 
substantial agreement, and 0.81-1.00 almost-perfect 
agreement.14 
This study follows the STrengthening the Reporting 
of OBservational studies in Epidemiology (STROBE) 
checklist15 and the REporting of studies Conducted 
using Observational Routinely-collected health Data 
(RECORD) Statement (Appendix 2) for reporting the 
findings.16
Results. Family Medicine clinics in KFSH & RC 
were selected following the feasibility assessment. 
Five hundred records meeting the inclusion criteria 
were reviewed. All the necessary information from 
each patient’s record was available in the Integrated 
Clinical Information System. In the feasibility study, 
all the outcomes were observed at least once in a total 
of 500 patients, except for outcomes 7, 8, and 10 
(Table 1). However, none of the outcome measures were 
excluded from the pilot and main studies, because it 
was considered possible that outcomes 7, 8, and 10 may 
appear when screening a higher number of records.
The findings from this phase of the research indicated 
that the pilot study was feasible and likely to provide a 
random sample, and all the information needed for the 
outcomes was available in one system. Continuation to 
the pilot and main phases of the study was therefore 
initiated without the exclusion of any of the outcome 
measures.
Pilot retrospective study. In the pilot retrospective 
study, a random sample of 200 records was selected 
from the Family Medicine clinics in KFSH & RC. 
The overall period prevalence rate of patients with at 
least one medication error over 15 months was 10% 
(95% CI 5.8-14.2). The overall period prevalence rate 
of medication errors over 15 months was 16% (95% 
CI 8.2-23.8). The pilot study suggested that clinically 
important errors commonly occurred in the medicine 
management of adults. The highest risk of prescription 
errors was observed in asthma patients who had been 
prescribed a ß-blocker. A monitoring error was found in 
one patient receiving lithium for at least 3 months; the 
patient did not have a recorded check of their lithium 
concentrations in the previous 3 months. Risk factors 
that significantly predicted the overall proportion of 
patients at the risk of medication errors were age ≥65 
years and OTC medication use; however, the obtained 
data suggested that other factors may be identified in 
the larger planned follow-up study.
The main retrospective cohort study. A total of 4,398 
patients visited the Family Medicine department one 
month prior to data collection. The required information 
from 2,000 electronic records was collected after the 
exclusion of patients who do not meet the inclusion 
criteria (Figure 1).
The percentage of adults in the age range 18-64 years 
was 83.85% and the percentage of those aged 65 years or 
older was 16.15%. The majority of the study population 
was of Saudi nationality (67.2%). Table 2 summarizes 
the participants’ characteristics. The agreement between 
the 2 independent data extractors dealing with the 200 
EHRs was substantial (Kappa 0.8). All discrepancies 
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were resolved by discussion and the double-checking of 
records.
Table 3 summarizes the prevalence of each outcome 
measure. A total of 162 prescribing/monitoring errors 
were found during the study period. The overall period 
prevalence of patients with at least one medication error 
over 15 months was 5.85% (95% CI 4.8-6.9), while the 
overall period prevalence of medication errors over 15 
months was 8.1% (95% CI 6.5-9.7).
Risk factors that significantly predicted the 
overall proportion of patients at risk of experiencing 
medications errors were: i) age of ≥65 years, ii) male 
gender, iii) Saudi nationality, and iv) using ≥5 drugs 
(Table 4). Risk factors that significantly predicted the 
overall proportion of patients who were at risk of 
experiencing medication errors were physicians’ male 
gender and Saudi nationality (Table 5). Table 5 also 
summarizes the risk factors for individual errors.
Discussion. Clinically important errors were 
observed commonly in medicine management. A 
random sample of 2,000 patient records was selected, 
resulting in the identification of 162 clinically important 
errors in medicine management. The overall period 
prevalence of patients with at least one medication error 
Figure 1 - Cohort study flowchart outlines and sample enrollment.
Table 2 - Cohort study participants’ demographic characteristics.
Variables n     (%)
Age (years)
18-64 1,677 (83.9)
≥65 323 (16.2)
Mean 49.9
95% confidence intervals 48.2 to 49.6
Gender
Male 698 (34.9)
Female 1,302 (65.1)
Nationality 
Saudi 1,344 (67.2)
Non-Saudi 656 (32.8)
Polypharmacy
Yes: ≥5 medications 1,115 (55.8)
No: 1-4 medications 885 (44.3)
OTC medicines
Yes: using OTC 1,899 (95.0)
No: not using OTC 101   (5.1)
Diagnosis 
Cardiac and vascular disorder 
Cardiac arrhythmias 18   (0.9)
Dyslipidemia 819 (41.0)
Essential hypertension 816 (40.8)
Heart failure 14   (0.7)
Ischemic heart disease 69   (3.5)
Pulmonary disorder
Asthma 250 (12.5)
COPD 5   (0.3)
Rhinitis 324 (16.2)
Psychiatric disorder 
Depression 164   (8.2)
Dementia 17   (0.9)
Gastrointestinal disorder
Ulcer 5   (0.3)
Gastritis 90   (4.5)
History of Helicobacter pylori  22   (1.1)
Renal disorder 
Chronic kidney disease 60   (3.0)
Arthritic disorder 
Osteoarthritis 180   (9.0)
Osteoporosis 44   (2.2)
Endocrine disorder 
Hypo/hyperthyroidism 353 (17.7)
Diabetes mellitus 595 (29.8)
OTC - over-the-counter (medications), COPD - chronic 
obstructive pulmonary disease
over 15 months was 5.85% (95% CI 4.8-6.9), while the 
overall period prevalence of medication errors was 8.1% 
(95% CI 6.5-9.7). The highest risk of prescription errors 
was in Outcome 2a: ‘patients with asthma who had 
been prescribed a ß-blocker’. However, for monitoring 
errors, the highest risk was in Outcome 7: ‘patients 
receiving lithium for at least 3 months, who did not 
have a recorded check of their lithium concentrations 
in the previous 3 months’.
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Table 3 - Cohort study period prevalence of each primary, secondary, composite and revised updated outcome measure described using numerators, 
denominators, and percentage, at patient level. 
Outcome measures Numerator Denominator Proportion of each outcome 
95% confidence interval
Primary outcomes
1. Patients with a history of peptic ulcer who have been prescribed a non-
selective NSAID without co-prescription of a PPI
  0   4 0
(2a) Patients with asthma who have been prescribed a beta-blocker   7   13 53.8; 95% CI 25.5 to 85.2
3. Patients aged 75 years and older who have been prescribed an ACE 
inhibitor or a loop diuretic long-term, who have not had a computer-recorded 
check of their renal function and electrolytes in the previous 15 months
  0   11 0
Secondary outcomes
(2b) Patients with asthma (and no history of CHD) who had been prescribed 
a beta-blocker
21 241 8.7; 95% CI 5.1 to12.3
4. Proportions of women with a past medical history of venous or arterial 
thrombosis who had been prescribed the combined oral contraceptive pill
  0   4 0
5. Patients receiving methotrexate for at least 3 months who had not had a 
full blood count recorded (5a), or liver function test (5b), in the previous 3 
months
(5a) 0
(5b) 0
(5a) 14
(5b) 14
(5a) 0
(5b) 0
6. Patients receiving warfarin for at least 3 months who had not had a 
recorded check of their INR in the previous 12 weeks
  4 16 25.0; 95% CI 1.2 to 48.8
7. Patients receiving lithium for at least 3 months who had not had a recorded 
check of their lithium concentrations in the previous 3 months
  2 2 100.0; 95% CI 100.0 to 100.0
8. Patients receiving amiodarone for at least 6 months who had not had a 
thyroid function test in the previous 6 months
  0 0 Not calculable
9. Patients receiving prescriptions of methotrexate without instructions that 
the drug should be taken every week
  0 14 0
10. Patients receiving prescriptions of amiodarone for at least 1 month who 
are receiving a dose of more than 200 mg per day
  0 0 Not calculable
Composite secondary outcome measures
11. Patients with at least one prescription problem (a combination of 
outcome measures 1, 2, or 4)
28 259 10.8; 95% CI 7.0 to 14.6
12. Patients with at least one monitoring problem (a combination of outcome 
measures 3, 5, 6, 7, and 8)
  6 43 13.95; 95% CI 3.2 to 24.7
Period prevalence 68 total number of 
errors
2000 total 
patients 
3.4; 95% CI 2.2 to 4.6
Period prevalence Total of 33 patients 
with at least one error
2,000 total 
patients
1.65; 95% CI 1.1 to 2.2
Additional revised updated outcomes measures 
13. Prescription of an oral NSAID, without co-prescription of an ulcer-
healing drug, to a patient aged ≥65 years
52 269 19.3; 95% CI 14.6 to 24.1
14. Prescription of an anti-platelet drug without co-prescription of an ulcer-
healing drug, to a patient with a history of peptic ulceration
  1 4 25.0; 95% CI  -54.6 to104.6
15. Prescription of warfarin or NOAC, in combination with an oral NSAID   2 32 6.25; 95% CI -2.6 to 15.1
16. Prescription of warfarin or NOAC and an anti-platelet drug in 
combination without co-prescription of an ulcer-healing drug
11 22 50.0; 95% CI 27.3 to 72.7
17. Prescription of aspirin in combination with another anti-platelet drug 
without co-prescription of an ulcer-healing drug
23 344 6.7; 95% CI 4.0 to 9.3
18. Prescription of a long-acting beta-2 agonist inhaler (excluding 
combination products with inhaled corticosteroid) to a patient with asthma 
who is not also prescribed an inhaled corticosteroid
  0 0 Not calculable
19. Prescription of an oral NSAID to a patient with heart failure   3 14 21.4; 95% CI -3.15 to 46.0
20. Prescription of antipsychotics for >6 weeks in a patient aged ≥65 years 
with dementia but not psychosis
  2 17 11.8; 95% CI -5.3 to 28.8
21. Prescription of an oral NSAID to a patient with eGFR <45   0 38 0
Overall period prevalence 162 total number of 
errors
2000 total 
patients
8.1; 95% CI 6.5 to 9.7
Overall period prevalence Total of 117 patients 
with at least one error
2,000 total 
patients
5.85; 95% CI 4.8 to 6.9
ACE -  angiotensin converting, CHD -  coronary heart disease, eGFR -  estimated Glomerular Filtration Rate, INR -  international normalized ratio, 
NOAC -  New Oral Anti-coagulant, NSAID -  non-steroidal anti-inflammatory drug, PPI  - proton-pump inhibitor
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Table 5 - Cohort study association between physician-related risk factors and patients at risk of errors outcomes. (Data obtained from logistic regression 
model). 
Outcome 
number
Age (years)
(≥51/18-50)
OR; 95% CI
P-value Gender
(male/female) 
OR; 95% CI
P-value Nationality
(Saudi/non-Saudi)
OR; 95% CI
P-value Certificate  
(American, British, 
Canadian, Jordanian 
certified, or none)
OR; 95% CI
P-value Years of 
experience 
(≥10/1-9)
OR; 95% CI
P-value Number
(≥1/1)
OR; 95% CI
P-value
Overall patients at risk of experiencing medications errors
1.0; 0.8 to 1.3 0.84 1.6; 1.3 to 2.1 0.00 1.9; 1.5 to 2.5 0.00 1.0; 0.9 to 1.2 0.49 1.1; 0.9 to 1.4 0.39 0.5; 0.4 to 0.6 0.00
Number of individual patients at risk outcome
2a 0.6; 0.15 to 2.2 0.42 1.7; 0.45 to 6.55 0.42 2.85; 0.9 to 9.4 0.09 1.3; 0.7 to 2.3 0.41 1.2; 0.35 to 4.2 0.74 0.3; 0.1 to 1.1 0.08
2b 1.4; 0.9 to 1.9 0.06 1.1; 0.8 to 1.5 0.65 0.9; 0.6 to 1.3 0.59 1.05; 0.9 to 1.2 0.49 1.0; 0.75 to 1.4 0.84 1.05; 0.7 to 1.6 0.79
3 1.5; 0.4 to 6.2 0.54 1.1; 0.25 to 4.5 0.92 1.1; 0.2 to 5.6 0.88 1.0; 0.5 to 2.0 0.98 0.7; 0.2 to 2.8 0.62 0.4; 0.1 to 1.55 0.19
4 0.8; 0.1 to 8.5 0.83 0.3; 0.0 to 3.55 0.36 NA - 0.3; 0.05 to 2.0 0.23 0.35; 0.0 to 3.9 0.39 NA -
5a 1.9; 0.6 to 6.1 0.31 0.4; 0.1 to 1.25 0.11 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 3.2; 0.7 to 14.8 0.14 0.6; 0.15 to 2.0 0.38
5b 1.9; 0.6 to 6.1 0.31 0.4; 0.1 to 1.25 0.11 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 3.2; 0.7 to 14.8 0.14 0.6; 0.15 to 2.0 0.38
6 0.6; 0.15 to 2.2 0.42 1.1; 0.3 to 3.9 0.85 1.3; 0.3 to 4.8 0.72 0.8; 0.4 to 1.5 0.49 1.2; 0.35 to 4.2 0.74 1.1; 0.2 to 4.8 0.92
7 NA - NA - NA - NA - NA - 0.15; 0.0 to 2.5 0.19
9 1.9; 0.6 to 6.1 0.31 0.5; 0.2 to 1.8 0.30 1.3; 0.3 to 4.8 0.72 0.7; 0.4 to 1.4 0.33 1.9; 0.5 to 7.1 0.35 0.6; 0.15 to 2.0 0.38
11 1.3; 0.9 to 1.7 0.13 1.1; 0.8 to 1.5 0.56 0.9; 0.7 to 1.4 0.83 1.0; 0.9 to 1.2 0.54 1.0; 0.7 to 1.4 0.95 0.9; 0.7 to 1.4 0.95
12 1.1; 0.5 to 2.3 0.76 0.7; 0.3 to 1.4 0.29 1.2; 0.5 to 2.7 0.69 0.7; 0.5 to 1.1 0.13 1.7; 0.8 to 3.8 0.17 0.6; 0.3 to 1.2 0.15
13 0.9; 0.7 to 1.25 0.61 2.6; 1.8 to 3.7 0.00 2.7; 1.9 to 3.7 0.00 1.1; 0.9 to 1.3 0.23 1.4; 1.0 to 1.9 0.04 0.3; 0.2 to 0.4 0.00
15 0.7; 0.3 to 1.6 0.38 1.8; 0.7 to 4.7 0.19 1.5; 0.6 to 3.7 0.38 0.8; 0.55 to 1.3 0.45 1.1; 0.5 to 2.55 0.83 0.45; 0.2 to 1.0 0.06
16 0.6; 0.2 to 1.9 0.41 1.6; 0.5 to 5.2 0.42 1.9; 0.6 to 5.7 0.25 0.9; 0.6 to 1.6 0.87 0.9; 0.3 to 2.7 0.91 0.4; 0.15 to 1.0 0.06
17 0.9; 0.7 to 1.2 0.63 1.7; 1.3 to 2.3 0.00 1.9; 1.45 to 2.7 0.00 0.9; 0.85 to 1.1 0.78 0.9; 0.7 to 1.3 0.91 0.7; 0.5 to 0.9 0.01
19 0.7; 0.2 to 2.6 0.55 5.9; 0.7 to 46.4 0.09 5.2; 1.4 to 18.4 0.01 1.1; 0.6 to 2.0 0.79 1.6; 0.4 to 6.4 0.47 0.6; 0.15 to 2.0 0.38
20 0.8; 0.2 to 2.6 0.67 7.2; 0.9 to 55.8 0.06 1.1; 0.3 to 4.2 0.85 1.05; 0.6 to 1.8 0.86 0.3; 0.1 to 1.2 0.09 0.3; 0.1 to 0.8 0.01
21 0.8; 0.4 to 1.8 0.62 3.6; 1.2 to 10.6 0.02 2.9; 1.4 to 6.5 0.01 1.3; 0.9 to 1.9 0.16 1.9; 0.8 to 4.6 0.14 0.4; 0.2 to 0.75 0.01
NA - no association. OR = 1. Outcome number 2 has 2 parts: (2a) and (2b). Outcome number 5 has 2 parts (5a) and (5b)
Table 4 - Cohort study association between patient and medication-related risk factors and patients at risk of errors outcomes. (Data obtained from logistic 
regression model). 
Outcome 
number
Age 
(≥65/18 to 64 years)
OR; 95% CI
P-value Gender
(male /female) 
OR; 95% CI
P-value Nationality 
(Saudi/non-Saudi)
OR; 95% CI
P-value Polypharmacy 
(yes/no)
OR; 95% CI
P-value OTC 
(yes/no)
OR; 95% CI
P-value
Overall patients at risk of experiencing medications errors
27.2; 18.6 to 39.85 0.00 1.9; 1.5 to 2.25 0.00 2.7; 2.2 to 3.3 0.00 4.7; 3.8 to 5.8 0.00 0.8; 0.55 to 1.25 0.38
Number of individual patients at risk outcome
1 15.7; 1.6 to 151.5 0.02 5.6; 0.6 to 54.1 0.14 1.5; 0.15 to 14.1 0.74 NA - NA -
2a 4.5; 1.5 to 13.5 0.01 2.2; 0.7 to 6.5 0.16 2.7; 0.6 to 12.2 0.19 NA - NA -
2b 1.5; 1.0 to 2.05 0.03 0.9; 0.7 to 1.2 0.46 1.3; 0.9 to 1.8 0.06 2.7; 2.0 to 3.7 0.00 1.4; 0.7 to 2.9 0.32
3 NA - 1.1; 0.3 to 3.65 0.91 NA - 3.6; 0.8 to 16.7 0.10 NA -
4 NA - NA - NA - 0.8; 0.1 to 5.6 0.82 NA -
5a NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 2.9; 0.8 to 10.5 0.10 NA -
5b NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 2.9; 0.8 to 10.5 0.10 NA -
6 5.3; 1.9 to 14.2 0.00 1.45; 0.5 to 3.9 0.46 3.4; 0.8 to 15.2 0.10 5.6; 1.3 to 24.8 0.02 NA -
7 NA - NA - NA - 0.8; 0.1 to 12.7 0.87 0.05; 0.0 to 0.85 0.04
9 NA - 0.5; 0.1 to 1.8 0.29 1.8; 0.5 to 6.5 0.37 1.9; 0.6 to 6.4 0.25 NA -
11 1.6; 1.2 to 2.2 0.00 0.95; 0.7 to 1.25 0.74 1.4; 1.1 to 1.9 0.02 2.8; 2.1 to 3.8 0.00 1.55; 0.8 to 3.1 0.22
12 3.9; 2.1 to 7.2 0.00 0.9; 0.5 to 1.7 0.75 2.2; 0.9 to 4.7 0.05 3.55; 1.6 to 7.7 0.00 2.3; 0.3 to 16.6 0.42
13 NA - 2.2; 1.7 to 2.9 0.00 9.9; 5.9 to 16.9 0.00 3.9; 2.8 to 5.3 0.00 0.8; 0.5 to 1.4 0.47
14 15.7; 1.6 to 151.5 0.02 5.6; 0.6 to 54.1 0.14 1.5; 0.15 to 14.1 0.74 NA - NA -
15 6.2; 3.0 to 12.45 0.00 1.5; 0.7 to 2.95 0.29 2.7; 1.0 to 6.9 0.05 4.4; 1.7 to 11.4 0.00 1.65; 0.2 to 12.3 0.62
16 4.4; 1.9 to 10.3 0.00 1.3; 0.55 to 3.0 0.55 3.1; 0.9 to 10.6 0.07 2.7; 1.0 to 7.4 0.05 1.1; 0.1 to 8.4 0.91
17 4.7; 3.6 to 6.1 0.00 2.3; 1.8 to 2.9 0.00 2.4; 1.8 to 3.25 0.00 5.2; 3.8 to 6.9 0.00 0.6; 0.4 to 0.9 0.02
19 5.3; 1.8 to 15.2 0.00 0.5; 0.1 to 1.8 0.29 6.4; 0.8 to 49.0 0.07 NA - NA -
20 NA - 2.1; 0.8 to 5.5 0.13 NA - 3.7; 1.1 to 13.0 0.04 0.4; 0.1 to 1.7 0.22
21 7.6; 3.9 to 14.6 0.00 1.4; 0.7 to 2.6 0.35 5.8; 1.8 to 18.9 0.00 14.7; 3.5 to 61.3 0.00 0.9; 0.2 to 4.0 0.95
NA - no association. OR = 1. Outcome number 2 has 2 parts: (2a) and (2b). Outcome number 5 has 2 parts (5a) and (5b)
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Patient and medication-related risk factors that 
significantly predicted the risk of errors were as follows: 
i) age ≥65 years, ii) male gender, iii) Saudi nationality, 
and iv) using ≥5 drugs. Physician-related risk factors 
that significantly predicted the risk of errors included 
male gender and Saudi nationality.
Strength. First, the list of clinically important errors 
in the prescription and monitoring stages that were used 
in this study was validated and then developed according 
to a systematic review, with inputs from research studies 
and experts, and a consensus on the overall burden 
and severity of iatrogenic harm in primary care, in 
the PINCER trial.17-19 Second, data collection of the 
total pilot study sample and 10% of the sample size 
of the cohort study was independently undertaken by 
2 reviewers, resulting in substantial agreement. Third, 
patient, medication, and physician-related factors that 
contribute to the risk of medication error occurrence 
were considered. Fourth, Outcome 5, methotrexate, 
was observed more frequently in the cohort study than 
the pilot study. Fifth, the large, nationally representative 
cohort of adults was followed-up over a 15-month 
period. Finally, this is the first epidemiological cohort 
study to focus on a pre-specified list of clinically 
important errors in community care settings in SA.
Study limitations. This study has some limitations 
that should be considered. First, outcomes 8 and 10 
were not observed; this could be attributed to the low 
prescription rate of amiodarone to cardiac arrhythmia 
patients. Second, data collection was performed 
manually due to the inability to ensure the accuracy and 
quality of patients’ information gathered electronically. 
Manual data extraction was also employed to avoid 
delays associated with the generation of the required 
anonymized data electronically from the electronic 
medical records department in KFSH & RC. Third, the 
results may not be generalizable because the study was 
conducted in a single community care setting in KSA. 
Fourth, the actual rates of use of these medications may 
be unknown as a large number of OTC medications 
can be brought in from outside the hospital and may 
not be recorded by physicians. Fifth, there is a risk of 
information bias, as the investigators relied on only 
EHR information for the identification and assessment 
of the outcomes of interest. Finally, there is inconsistency 
in the precision type between the period prevalence 
measure in the present cohort (namely, 95% CI) and 
that in the PINCER trial (namely, IQR); as a result, 
we compared the proportions alone without precisions.
Interpretation in the light of the wider published 
literature. Our results were compared to the baseline 
characteristics of the PINCER trial, as derived from 
the QRESEARCH database, which is one of the 
largest aggregate general practice electronic databases 
worldwide, comprising 487 general practices.20 The 
overall period prevalence of the first 12 clinically 
important errors in medicine management was 3.4% 
(95% CI 2.2-4.6) in this research, compared to the 
0.9% in the PINCER trial.20 
The distribution of each estimate for the outcome 
measures is as follows: In this study, higher period 
prevalence estimates were observed for the following: 
Outcomes 2a and 2b: asthma and ß-blocker, Outcome 
6: warfarin and international normalized ratio, 
Outcome 7: lithium and lithium level, Outcome 11: 
at least one prescription error, and Outcome 12: at 
least one monitoring error. In this study, we could not 
estimate the rates for the following outcomes, because 
there were no events: Outcome 1: peptic ulcer and 
NSAID without an ulcer-healing drug, Outcome 3: 
ACE inhibitor / diuretics and laboratory test, Outcome 
4: venous or arterial thromboembolism and arterial 
thrombosis and combined oral contraceptives, and 
Outcomes 5a and 5b: methotrexate and full blood 
count, and methotrexate and liver function test. For 
Outcome 8, amiodarone and thyroid function test, 
we observed no patients on amiodarone. This may 
reflect both the differences in the healthcare services 
provided in KSA and the UK and the varied methods 
of the extraction of data and outcomes between the 2 
studies. In the baseline characteristics of the PINCER 
trial, data were collected prospectively through a 
computer-recorded method and the level of accuracy 
and completeness was shown to be high.20,21 However, 
in this study, the data were collected retrospectively 
through manual data extraction. Akbarov et al22 in a 
cross-sectional study using linked records in the UK 
general practices, used 22 medication safety indicators 
(18 prescribing indicators with an overall prevalence 
as 5.45% and 4 monitoring indicators with an overall 
prevalence as 7.65%). In order to compare our study 
results with the findings from the previous study,22 it is 
important to have a consistent definition of numerator 
and denominator. Only 13 consistent indicators can be 
compared with the outcome measures employed in this 
study. The other 9 indicators were not used in our study, 
so a comparison between the overall outcome measures’ 
estimate and other study22 overall outcome measures’ 
estimates were not established.  This present study found 
higher period prevalence estimates for the following: 
Outcome 2a (asthma and ß-blocker), Outcome 6 
(warfarin and INR), Outcome 13 (aged ≥65 years using 
NSAID without an ulcer-healing drug), Outcome 
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15 (warfarin/NOAC and NSAID), and Outcome 19 
(heart failure and NSAID). In this study, we could not 
estimate the rates for the following outcomes, because 
there were no events: Outcome 1 (peptic ulcer and 
NSAID without ulcer-healing drug), Outcome 3 (ACE 
inhibitor/diuretics and lab test), Outcome 4 (venous or 
arterial thromboembolism and arterial thrombosis and 
combined oral contraceptives), Outcomes 5a and 5b 
(methotrexate and full blood count and methotrexate 
and liver function test), and Outcome 21 (eGFR 
<45 and NSAID). For outcome 8 (amiodarone and 
thyroid function test), no patient in this study was 
on amiodarone. For (outcome 18: long-acting beta-2 
agonist inhaler [excluding combination products with 
inhaled corticosteroid] to a patient with asthma who 
is not also prescribed an inhaled corticosteroid), all the 
study patients were on combination products with the 
inhaled corticosteroid.
Implications for research, policy, and practice. 
For healthcare professionals, there is a need for the 
following: i) training, education, and monitoring with 
the involvement of medication safety pharmacists in the 
community, ii) the implementation of computerized 
prescription with software integration for the detection 
of clinically important errors in medicine management 
during prescription entry, iii) the provision of a record 
of current medication lists for each patient in the 
community, and vi) empowerment and education 
among patients and the public, particularly among 
those with chronic diseases and polypharmacy, to 
increase the knowledge of medication safety. For 
patients, tools and technology should be employed, 
particularly for monitoring and follow-up, as most 
medication errors occur in this stage due to irregular 
outpatient visits; there is a need for patients’ current 
medication lists to be shown at each pharmacy visit. 
Further study is required for the following: i) to 
replicate the outcome measures in different community 
care contexts in KSA, to increase the generalizability 
of our findings and ii) to further explore error-related 
adverse events, and their causes and prevalence, in 
community care settings in SA.  Consideration should 
also be given to undertaking interventional studies 
aimed at reducing the risk of medication errors. A trial 
based on the PINCER trial could be conducted in 
the KFSH & RC. Such an initiative would have to be 
modified to a parallel group design, as opposed to the 
cluster, randomized control design used in the PINCER 
trial. A random sample of records of individuals could 
be selected and randomized to receive either simple 
feedback or pharmacist intervention. The first challenge 
would be to identify, by manual or computer-generated 
methods, those patients who are potentially at risk of 
clinically important errors in medicine management. In 
the simple feedback arm of this trial, physicians would 
be given manual or computer-generated feedback on 
patients who are at potential risk of clinically important 
errors, together with brief written educational materials 
explaining the importance of each type of error. In 
the pharmacist-intervention arm, pharmacists should 
provide simple feedback plus educational outreach 
“academic detailing”, while considering the human 
error theory and provide support in order to correct 
and prevent medication errors. The choice of manual or 
computer-generated methods is likely to be challenging, 
as the computer-generated method has not been used 
till date in the KFSH & RC. This proposed research 
initiative should aim to do the following: i) calculate the 
prevalence of the outcome measures before and after the 
intervention and ii) decrease the number of clinically 
important errors as much as possible.
In conclusions, this study shows that clinically 
important medication errors occur commonly, and 
such mistakes could potentially harm patients’ health. 
Patient-related risk factors that significantly predicted 
the overall proportion of patients at risk of experiencing 
medication errors were as follows: i) age ≥65 years, ii) 
male gender, iii) Saudi nationality, and iv) using ≥5 
drugs. Physician-related risk factors that significantly 
predicted the overall proportion of patients at risk of 
errors were male gender and Saudi nationality. Future 
research should aim to replicate these findings in other 
community care contexts in SA, to further explore 
any associated error-related adverse events, and also 
to develop and evaluate an intervention aimed at 
decreasing the incidence of clinically important errors 
in medicine management in SA.
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Appendix 1 - Data collection form of medication errors study.
 
A) Demographic and basic information
Patient characteristics 
Patient code
Age Years ________
Gender M______ F __________
Nationality Saudi Non-Saudi  
Diagnosis or past medical history 
Anaemia Back pain 
Allergic rhinitis Osteoporosis
Benign prostatic hypertrophy (BPH) Osteoarthritis
Bronchial asthma Type 1 diabetes mellitus
Chronic obstructive pulmonary disease (COPD) Type 2 diabetes mellitus
Coronary artery disease (CAD) Vitamin D deficiency
Depression Hypertriglyceridemia
Essential primary hypertension (HTN) Hyperlipidaemia
Gastroesophageal reflux disease (GERD) Other:
Heart failure (HF)
Hyperthyroidism
Hypothyroidism
Polypharmacy at any point (≥5 medications) Yes No
Over-the-counter medication Yes No
Physician characteristics 
Physician code
Physician number
B) outcome measures
Numerator Yes/no Denominator Yes/no Comment
Primary, secondary and composite outcome measures
1 History of peptic ulcer prescribed an non-
steroidal anti-inflammatory drug (NSAID) 
without a proton-pump inhibitor (PPI)
History of peptic ulcer without a PPI
2a Asthma prescribed a β-blocker Asthma 
2b Asthma and not CHD prescribed a 
β-blocker
Asthma and not CHD 
 3  Aged ≥75 on long term ACE inhibitors 
or diuretics without urea and electrolyte 
monitoring in the previous 15 months
Aged ≥75 on long term ACE inhibitors or 
diuretics
4 History of venous or arterial 
thromboembolism and arterial thrombosis 
prescribed combined oral contraceptives 
(Female)
History of venous or arterial 
thromboembolism and arterial thrombosis 
(female)
5a Methotrexate for ≥ 3 months without a full 
blood count in last 3 months
Methotrexate for ≥3 months 
5b Methotrexate for ≥ 3 months without an 
liver function test in last 3 months
Methotrexate for ≥3 months 
6 Warfarin for ≥ 3 months without an 
international normalised ratio (INR) in last
Warfarin for ≥3 months 
7 Lithium for ≥ 3 months without a lithium 
level in last 3 months
Lithium for ≥3months 
8 Amiodarone for ≥ 6 months without a 
thyroid function test in the last 6 months
Amiodarone for ≥6 months
9 Methotrexate without instructions to take 
weekly
Patient prescribed methotrexate 
10 Amiodarone for ≥ 1 month at a dose of more 
than 200mg/day
Amiodarone for ≥1 month 
11 Patients with at least one prescription 
problem (a combination of outcome 
measures 1, 2, or 4)
12 Patients with at least one monitoring 
problem (a combination of outcome 
measures 3, 5, 6, 7, and 8)
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Numerator Yes/no Denominator Yes/no Comment
Revised updated outcome measures
13 Patients aged ≥65 years prescribed an oral 
NSAID without co-prescription of an ulcer-
healing drug
Patients aged ≥65 years without co-
prescription of an ulcer-healing drug
14 History of peptic ulcer prescribed an 
antiplatelet drug without co-prescription of 
an ulcer-healing drug
History of peptic ulceration without co-
prescription of an ulcer-healing drug
15 Prescribed warfarin or NOAC in 
combination with an oral NSAID
Prescribed warfarin or NOAC
16 Prescribed warfarin or NOAC and an 
antiplatelet drug in combination without co-
prescription of an ulcer-healing drug
Prescribed warfarin or NOAC without co-
prescription of an ulcer-healing drug
17 Prescribed aspirin in combination with 
another antiplatelet drug without co-
prescription of an ulcer-healing drug
Prescribed aspirin without co-prescription 
of an ulcer-healing drug
18 Asthma prescribed a long-acting beta-2 
agonist inhaler who is not also prescribed an 
inhaled corticosteroid
Asthma prescribed a long-acting beta-2 
agonist inhaler
19 Heart failure prescribed an oral NSAID Heart failure
20 Patients aged ≥65 years with dementia but 
not psychosis prescribed antipsychotic drugs 
for >6weeks
Patients aged ≥65 years with dementia but 
not psychosis
21 Patients with an eGFR <45 prescribed an 
oral NSAID
Patients with an eGFR <45
If the patient had a history of the following: 
Peptic ulcer - see outcome 1 and 14
Asthma - see outcome 2a, 18
OR Asthma and not coronary heart disease (CHD) - see outcome 2b, 18
A female with venous or arterial thromboembolism and arterial thrombosis - see outcome 4
Patient aged ≥65 years - see outcome 13
Patient aged ≥65 years with dementia - see outcome 20
Heart failure - see outcome 19
eGFR <45 - see outcome 21
If the patient was on the following medications
Aged ≥75 years and on angiotensin converting enzyme (ACE) inhibitors or diuretics - see outcome 3
Methotrexate - see outcome 5a, 5b & 9
Warfarin - see outcome 6, 15 & 16
New Oral Anti-Coagulant (NOAC) - see outcome 15 & 16
Lithium - see outcome 7
Amiodarone - see outcome 8 &10
Aspirin - see outcome 17
ACE - angiotensin converting enzyme,  CHD - coronary heart disease,  eGFR - estimated glomerular filtration rate,  INR - international normalized 
ratio,  NOAC - new oral anti-coagulant,  NSAID - non-steroidal anti-inflammatory drug,  PPI - proton-pump inhibitor,  PINCER - pharmacist-led 
information technology intervention. Outcome number 5 has 2 parts (5a) and (5b)
Appendix 1 - Data collection form of medication errors study. (continued)
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Appendix 2 - The RECORD statement-checklist of items, extended from the STROBE statement that should be reported in observational studies using 
routinely collected health data.
Item Item 
No.
STROBE items Location in 
manuscript 
where items 
are reported
RECORD items Location in 
manuscript 
where items 
are reported
Title and 
abstract 
1 (a) Indicate the study’s design with a commonly 
used term in the title or the abstract
 (b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found
1 RECORD 1.1: The type of data used should 
be specified in the title or abstract. When 
possible, the name of the databases used should 
be included.
RECORD 1.2: If applicable, the geographic 
region and timeframe within which the study 
took place should be reported in the title or 
abstract.
RECORD 1.3: If linkage between databases 
was conducted for the study, this should be 
clearly stated in the title or abstract.
1
Introduction
Background 
rationale
2 Explain the scientific background and rationale for 
the investigation being reported
5
Objectives 3 State specific objectives, including any prespecified 
hypotheses
5
Methods
Study Design 4 Present key elements of study design early in the 
paper
5
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection
6
Participants 6 (a) Cohort study - Give the eligibility criteria, 
and the sources and methods of selection of 
participants. Describe methods of follow-up
Case-control study - Give the eligibility criteria, 
and the sources and methods of case ascertainment 
and control selection. Give the rationale for the 
choice of cases and controls
Cross-sectional study - Give the eligibility criteria, 
and the sources and methods of selection of 
participants
(b) Cohort study - For matched studies, give 
matching criteria and number of exposed and 
unexposed
Case-control study - For matched studies, give 
matching criteria and the number of controls per 
case
6 RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) should 
be listed in detail. If this is not possible, an 
explanation should be provided. 
RECORD 6.2: Any validation studies of 
the codes or algorithms used to select the 
population should be referenced. If validation 
was conducted for this study and not published 
elsewhere, detailed methods and results should 
be provided.
RECORD 6.3: If the study involved linkage 
of databases, consider use of a flow diagram 
or other graphical display to demonstrate the 
data linkage process, including the number of 
individuals with linked data at each stage.
-
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable.
6 RECORD 7.1: A complete list of codes 
and algorithms used to classify exposures, 
outcomes, confounders, and effect modifiers 
should be provided. If these cannot be 
reported, an explanation should be provided.
Data sources/ 
measurement
8 For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement).
Describe comparability of assessment methods if 
there is more than one group
7
Bias 9 Describe any efforts to address potential sources 
of bias
8
Study size 10 Explain how the study size was arrived at 8
Quantitative 
variables
11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen, and why
-
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Statistical 
methods
12 (a) Describe all statistical methods, including those 
used to control for confounding
(b) Describe any methods used to examine 
subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study - If applicable, explain how loss to 
follow-up was addressed
Case-control study - If applicable, explain how 
matching of cases and controls was addressed
Cross-sectional study - If applicable, describe 
analytical methods taking account of sampling 
strategy
(e) Describe any sensitivity analyses
8
Data access 
and cleaning 
methods
8 RECORD 12.1: Authors should describe the 
extent to which the investigators had access 
to the database population used to create the 
study population.
RECORD 12.2: Authors should provide 
information on the data cleaning methods used 
in the study.
8
Linkage RECORD 12.3: State whether the study 
included person-level, institutional-level, 
or other data linkage across two or more 
databases. The methods of linkage and 
methods of linkage quality evaluation should 
be provided.
-
Results
Participants 13 (a) Report the numbers of individuals at each 
stage of the study (e.g., numbers potentially 
eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and 
analysed)
(b) Give reasons for non-participation at each stage.
(c) Consider use of a flow diagram
10 RECORD 13.1: Describe in detail the 
selection of the persons included in the study 
(i.e., study population selection) including 
filtering based on data quality, data availability 
and linkage. The selection of included persons 
can be described in the text and/or by means of 
the study flow diagram.
-
Descriptive data 14 (a) Give characteristics of study participants (e.g., 
demographic, clinical, social) and information on 
exposures and potential confounders
(b) Indicate the number of participants with 
missing data for each variable of interest
(c) Cohort study - summarise follow-up time (e.g., 
average and total amount)
11
Outcome data 15 Cohort study - Report numbers of outcome events 
or summary measures over time
Case-control study - Report numbers in each 
exposure category, or summary measures of 
exposure
Cross-sectional study - Report numbers of outcome 
events or summary measures
12
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g., 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included
(b) Report category boundaries when continuous 
variables were categorized
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period
11
Other analyses 17 Report other analyses done—e.g., analyses of 
subgroups and interactions, and sensitivity analyses
12
Appendix 2 - Data collection form. (continued)
 www.smj.org.sa    Saudi Med J 2019; Vol. 40 (2)
Medication errors in adults in community care  ... Assiri et al
Discussion
Key results 18 Summarize key results with reference to study 
objectives
13
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any 
potential bias
13 RECORD 19.1: Discuss the implications of 
using data that were not created or collected 
to answer the specific research question(s). 
Include discussion of misclassification bias, 
unmeasured confounding, missing data, and 
changing eligibility over time, as they pertain 
to the study being reported.
13
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other 
relevant evidence
14
Generalisability 21 Discuss the generalisability (external validity) of the 
study results
14
Other Information
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based
17
Accessibility 
of protocol, 
raw data, and 
programming 
code
RECORD 22.1: Authors should provide 
information on how to access any supplemental 
information, such as the study protocol, raw 
data, or programming code.
-
Copyright permission from PLoS Medicine. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. the RECORD Working 
Committee.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement.  PLoS Med 2015; 12: 
e1001885. doi: 10.1371/journal.pmed.1001885.
*Checklist is protected under Creative Commons Attribution (CC BY) license.
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